National and state treatment need and capacity for opioid agonist medication-assisted treatment
Author
Abstract
Suggested Citation
DOI: 10.2105/AJPH.2015.302664
Download full text from publisher
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- David Cho & Daniel I. García & Joshua Montes & Alison E. Weingarden, 2021. "Labor Market Effects of the Oxycodone-Heroin Epidemic," Finance and Economics Discussion Series 2021-025, Board of Governors of the Federal Reserve System (U.S.).
- Meinhofer, Angélica & Witman, Allison E., 2018. "The role of health insurance on treatment for opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion," Journal of Health Economics, Elsevier, vol. 60(C), pages 177-197.
- Johanna Catherine Maclean & Brendan Saloner, 2019.
"The Effect of Public Insurance Expansions on Substance Use Disorder Treatment: Evidence from the Affordable Care Act,"
Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 38(2), pages 366-393, March.
- Maclean, J. Catherine & Saloner, Brendan, 2017. "The Effect of Public Insurance Expansions on Substance Use Disorder Treatment: Evidence from the Affordable Care Act," IZA Discussion Papers 10745, Institute of Labor Economics (IZA).
- Johanna Catherine Maclean & Brendan Saloner, 2017. "The Effect of Public Insurance Expansions on Substance Use Disorder Treatment: Evidence from the Affordable Care Act," NBER Working Papers 23342, National Bureau of Economic Research, Inc.
- Ellen Bouchery & Judith Dey, "undated". "Substance Use Disorder Workforce," Mathematica Policy Research Reports 47d4d14a7a32485eba249dfb3, Mathematica Policy Research.
- Caroline A King & Honora Englander & P Todd Korthuis & Joshua A Barocas & K John McConnell & Cynthia D Morris & Ryan Cook, 2021. "Designing and validating a Markov model for hospital-based addiction consult service impact on 12-month drug and non-drug related mortality," PLOS ONE, Public Library of Science, vol. 16(9), pages 1-14, September.
- Mary A. Burke, 2019. "Access to medication-assisted treatment for opioid use disorder: is Rhode Island different, and why?," Current Policy Perspectives 19-2, Federal Reserve Bank of Boston.
- Mary A. Burke & Riley Sullivan, 2020. "Medication-assisted Treatment for Opioid Use Disorder in Rhode Island: Who Gets Treatment, and Does Treatment Improve Health Outcomes?," New England Public Policy Center Research Report 20-3, Federal Reserve Bank of Boston.
- Aparna Soni & Lindsey Bullinger & Christina Andrews & Amanda Abraham & Kosali Simon, 2024. "The impact of state Medicaid eligibility and benefits policy on neonatal abstinence syndrome hospitalizations," Contemporary Economic Policy, Western Economic Association International, vol. 42(1), pages 25-40, January.
- Jayme E. Walters & Aubrey E. Jones & Aaron R. Brown & Dorothy Wallis, 2022. "Impacts of the COVID-19 Pandemic on a Rural Opioid Support Services Program," IJERPH, MDPI, vol. 19(18), pages 1-12, September.
- Guo, Jiapei & Kilby, Angela E. & Marks, Mindy S., 2024. "The impact of scope-of-practice restrictions on access to medical care," Journal of Health Economics, Elsevier, vol. 94(C).
- Emanuel Krebs & Jeong E. Min & Elizabeth Evans & Libo Li & Lei Liu & David Huang & Darren Urada & Thomas Kerr & Yih-Ing Hser & Bohdan Nosyk, 2017. "Estimating State Transitions for Opioid Use Disorders," Medical Decision Making, , vol. 37(5), pages 483-497, July.
- Mitchell, Penelope & Samsel, Steven & Curtin, Kevin M. & Price, Ashleigh & Turner, Daniel & Tramp, Ryan & Hudnall, Matthew & Parton, Jason & Lewis, Dwight, 2022. "Geographic disparities in access to Medication for Opioid Use Disorder across US census tracts based on treatment utilization behavior," Social Science & Medicine, Elsevier, vol. 302(C).
- Matthew T. Knowles, 2022. "How access to addictive drugs affects the supply of substance abuse treatment: Evidence from Medicare Part D," Health Economics, John Wiley & Sons, Ltd., vol. 31(8), pages 1649-1675, August.
More about this item
Keywords
buprenorphine; methadone; narcotic analgesic agent; capacity building; health service; health survey; human; opiate substitution treatment; Opioid-Related Disorders; statistics and numerical data; United States; Analgesics; Opioid; Buprenorphine; Capacity Building; Health Services Needs and Demand; Health Surveys; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; United States;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:aph:ajpbhl:10.2105/ajph.2015.302664_4. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Christopher F Baum (email available below). General contact details of provider: https://www.apha.org .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.